H. Lundbeck A/S (HLUBF)
8.35
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
H. Lundbeck Enterprise Value : 9.042B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 9.042B |
| November 12, 2026 | 9.042B |
| November 11, 2026 | 8.635B |
| November 10, 2026 | 8.635B |
| November 09, 2026 | 8.635B |
| November 06, 2026 | 7.554B |
| November 05, 2026 | 7.554B |
| November 04, 2026 | 7.554B |
| November 03, 2026 | 7.554B |
| November 02, 2026 | 7.554B |
| October 30, 2026 | 7.554B |
| October 29, 2026 | 7.554B |
| October 28, 2026 | 7.554B |
| October 27, 2026 | 7.554B |
| October 26, 2026 | 7.554B |
| October 23, 2026 | 7.554B |
| October 22, 2026 | 7.554B |
| October 21, 2026 | 7.554B |
| October 20, 2026 | 7.554B |
| October 19, 2026 | 7.554B |
| October 16, 2026 | 7.554B |
| October 15, 2026 | 7.554B |
| October 14, 2026 | 7.554B |
| October 13, 2026 | 7.554B |
| October 12, 2026 | 7.554B |
| Date | Value |
|---|---|
| October 09, 2026 | 7.554B |
| October 08, 2026 | 7.554B |
| October 07, 2026 | 7.107B |
| October 06, 2026 | 7.107B |
| October 05, 2026 | 7.107B |
| October 02, 2026 | 7.107B |
| October 01, 2026 | 7.107B |
| September 30, 2026 | 7.107B |
| September 29, 2026 | 7.454B |
| September 28, 2026 | 7.454B |
| September 25, 2026 | 7.454B |
| September 24, 2026 | 7.454B |
| September 23, 2026 | 7.454B |
| September 22, 2026 | 7.454B |
| September 21, 2026 | 7.454B |
| September 18, 2026 | 7.454B |
| September 17, 2026 | 7.454B |
| September 16, 2026 | 7.454B |
| September 15, 2026 | 7.454B |
| September 14, 2026 | 7.838B |
| September 11, 2026 | 7.613B |
| September 10, 2026 | 6.604B |
| September 09, 2026 | 6.604B |
| September 08, 2026 | 6.604B |
| September 04, 2026 | 6.604B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novo Nordisk A/S | 152.68B |
| ALK-Abello A/S | 7.898B |
| AstraZeneca PLC | 598.40B |
| ANI Pharmaceuticals, Inc. | 1.807B |
| Corcept Therapeutics, Inc. | 7.615B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 195.00M |
| Revenue (Quarterly) | 1.032B |
| Total Expenses (Quarterly) | 836.96M |
| EPS Diluted (Quarterly) | 0.1965 |
| Gross Profit Margin (Quarterly) | 81.66% |
| Profit Margin (Quarterly) | 18.90% |
| Earnings Yield | 7.59% |
| Operating Earnings Yield | 12.52% |
| Normalized Earnings Yield | 8.126 |